An observational study in Retroperitoneal Neoplasms, sponsored by The First Hospital of Jilin University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by The First Hospital of Jilin University · Observational
This is an observational, real-world registry study. The RETROR registry aims to establish a clinical database for patients with retroperitoneal tumors. We will systematically collect demographic information, comorbidities, preoperative imaging findings, perioperative parameters, pathological outcomes, adjuvant treatment, surgical complications, recurrence, metastasis, and long-term survival data. The registry will summarize clinical features, evaluate surgical outcomes, and explore prognostic factors of retroperitoneal tumors. Written informed consent will be obtained from all participants prior to enrollment.
The First Hospital of Jilin University is the lead sponsor of 185 studies on the registry; 96 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is a single-center real-world registry study. The study population consists of patients with preoperative imaging or pathological diagnosis of retroperitoneal tumors, without age or gender restriction. Clinical, imaging, pathological, treatment and follow-up data will be collected prospectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall Survival
Time from diagnosis to death from any cause
Time frame: Up to 5 years after enrollment
Plan to share: No — Individual participant data (IPD) will not be shared. Data sharing is restricted by institutional policy and patient privacy protection requirements. Aggregated study results may be published in peer-reviewed journals.
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Retroperitoneal Neoplasms
The First Hospital of Jilin University →